Andrea L Zaenglein Selected Research

Isotretinoin (Accutane)

9/2020	Lidose-Isotretinoin Administered Without Food Improves Quality of Life in Patients With Severe Recalcitrant Nodular Acne: An Open-Label, Single-Arm, Phase IV Study.
11/2019	An Open-label, Phase IV Study Evaluating Lidose-isotretinoin Administered without Food in Patients with Severe Recalcitrant Nodular Acne: Low Relapse Rates Observed Over the 104-week Post-treatment Period.
1/2018	Update in the management of acne in adolescence.
1/2017	Isotretinoin and Timing of Procedural Interventions: A Systematic Review With Consensus Recommendations.
8/2016	Standardized laboratory monitoring with use of isotretinoin in acne.
7/2014	Contraceptive use in acne.
6/2013	A phase IV, open-label study evaluating the use of triple-combination therapy with minocycline HCl extended-release tablets, a topical antibiotic/retinoid preparation and benzoyl peroxide in patients with moderate to severe acne vulgaris.
5/2009	Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action.
4/2008	Neutrophil gelatinase-associated lipocalin mediates 13-cis retinoic acid-induced apoptosis of human sebaceous gland cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrea L Zaenglein Research Topics

Disease

17	Acne Vulgaris 01/2022 - 09/2006
4	Atopic Dermatitis (Atopic Eczema) 03/2022 - 09/2016
2	Allergic Contact Dermatitis 07/2018 - 09/2011
2	Cicatrix (Scar) 01/2018 - 01/2017
1	Pain (Aches) 03/2022
1	Hidradenitis Suppurativa 01/2022
1	Ichthyosis (Xeroderma) 01/2021
1	Inflammation (Inflammations) 01/2018
1	Keloid 01/2017
1	Hypertrophic Cicatrix (Hypertrophic Scar) 01/2017
1	Pruritus (Itching) 09/2016
1	Hypercholesterolemia 08/2016
1	Hypertriglyceridemia 08/2016
1	Lentigo (Lentiginosis) 05/2015
1	Neoplasms (Cancer) 05/2009
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/2005
1	Warts (Wart) 11/2004

Drug/Important Bio-Agent (IBA)

9	Isotretinoin (Accutane)FDA LinkGeneric 09/2020 - 04/2008
7	RetinoidsIBA 01/2021 - 09/2006
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2018 - 09/2006
3	Combined Oral ContraceptivesIBA 01/2018 - 08/2010
2	crisaboroleIBA 03/2022 - 09/2016
2	Phosphodiesterase 4 InhibitorsIBA 03/2022 - 09/2016
2	Ointments (Pastes)IBA 03/2022 - 09/2016
2	Spironolactone (Aldactone)FDA LinkGeneric 01/2022 - 07/2014
2	Immunoglobulin A (IgA)IBA 09/2020 - 06/2013
2	Benzoyl Peroxide FDA LinkGeneric 10/2017 - 06/2013
2	Etanercept (Enbrel)FDA Link 05/2015 - 11/2004
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 06/2013 - 04/2008
1	Dapsone FDA Link 04/2021
1	Filaggrin ProteinsIBA 04/2020
1	Thymic Stromal LymphopoietinIBA 12/2019
1	Insulin-Like Growth Factor I (IGF-1)IBA 01/2018
1	CosmeceuticalsIBA 04/2017
1	CosmeticsIBA 04/2017
1	Acitretin FDA Link 01/2017
1	Type 4 Cyclic Nucleotide PhosphodiesterasesIBA 09/2016
1	Alanine (L-Alanine)FDA Link 08/2016
1	Hormones (Hormone)IBA 07/2014
1	AndrogensIBA 07/2014
1	Contraceptive Agents (Contraceptives)IBA 07/2014
1	TabletsIBA 06/2013
1	Minocycline (Cyclops)FDA LinkGeneric 06/2013
1	clindamycin phosphate (Clindets)FDA LinkGeneric 06/2013
1	PlasticsIBA 09/2011
1	Oral ContraceptivesIBA 08/2010
1	LipidsIBA 05/2009
1	EnzymesIBA 05/2009
1	Differentiation AntigensIBA 05/2009
1	Serine Proteases (Serine Protease)IBA 05/2009
1	Small Interfering RNA (siRNA)IBA 04/2008
1	Lipocalin-2IBA 04/2008

Therapy/Procedure

6	Therapeutics 11/2019 - 08/2010
2	Bathroom Equipment 07/2018 - 09/2011
1	Transjugular Intrahepatic Portasystemic Shunt 03/2020
1	Retreatment 11/2019
1	Dermatologic Surgical Procedures 01/2017
1	Dermabrasion 01/2017
1	Hair Removal (Depilation) 01/2017
1	Lasers (Laser) 01/2017
1	Duration of Therapy 08/2016
1	Contraception (Birth Control) 07/2014
1	Drug Therapy (Chemotherapy) 02/2005